High-dose dexamethasone during chemotherapy shows no significant cortisol changes in breast cancer.

This prospective pilot study enrolled 47 women with breast cancer receiving standard chemotherapy treatment. Participants received paclitaxel and dexamethasone as part of their chemotherapy treatment regimen. The study design utilized baseline measurements as the comparator for assessing physiological changes during the intervention period of chemotherapy. Weekly chemotherapy cycles served as the follow-up structure for data collection throughout the study.

The intervention involved intermittent high-dose dexamethasone administration during chemotherapy cycles of paclitaxel. The primary outcome focused on morning serum cortisol and adrenocorticotropic hormone (ACTH) concentrations. Results indicated an overall downward tendency during treatment; however, no statistically significant changes were observed in hormone levels. Effect size and absolute numbers were not reported.

Safety data regarding adverse events, serious adverse events, and discontinuations were not reported in the study. Tolerability information was also not reported by the investigators. A key limitation noted was the limitations of single cortisol measurements. These constraints impact the reliability of the hormonal assessment and generalizability of the findings for oncology care.

Practice relevance highlights the need for a longitudinal approach when assessing adrenal function in oncology patients receiving chemotherapy. The evidence remains early and observational in nature with limited sample size. Clinicians should recognize these limitations when considering adrenal function monitoring in similar populations of patients. Future research requires more robust data to confirm trends in this area of oncology.